- Home
- GFR vs RLMD Comparison
GFR vs RLMD Comparison
Compare GFR & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFR
- RLMD
- Stock Information
- Founded
- GFR 2018
- RLMD 2004
- Country
- GFR Canada
- RLMD United States
- Employees
- GFR N/A
- RLMD N/A
- Industry
- GFR
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- GFR
- RLMD Health Care
- Exchange
- GFR Nasdaq
- RLMD Nasdaq
- Market Cap
- GFR 330.9M
- RLMD 289.7M
- IPO Year
- GFR N/A
- RLMD N/A
- Fundamental
- Price
- GFR $5.09
- RLMD $3.98
- Analyst Decision
- GFR
- RLMD Hold
- Analyst Count
- GFR 0
- RLMD 2
- Target Price
- GFR N/A
- RLMD $1.00
- AVG Volume (30 Days)
- GFR 143.6K
- RLMD 1.8M
- Earning Date
- GFR 11-03-2025
- RLMD 11-13-2025
- Dividend Yield
- GFR N/A
- RLMD N/A
- EPS Growth
- GFR 252.40
- RLMD N/A
- EPS
- GFR 1.37
- RLMD N/A
- Revenue
- GFR $470,838,329.00
- RLMD N/A
- Revenue This Year
- GFR N/A
- RLMD N/A
- Revenue Next Year
- GFR $3.61
- RLMD N/A
- P/E Ratio
- GFR $3.76
- RLMD N/A
- Revenue Growth
- GFR N/A
- RLMD N/A
- 52 Week Low
- GFR $3.81
- RLMD $0.24
- 52 Week High
- GFR $7.87
- RLMD $4.34
- Technical
- Relative Strength Index (RSI)
- GFR 60.09
- RLMD 78.00
- Support Level
- GFR $4.26
- RLMD $2.42
- Resistance Level
- GFR $5.10
- RLMD $2.86
- Average True Range (ATR)
- GFR 0.26
- RLMD 0.43
- MACD
- GFR 0.04
- RLMD 0.15
- Stochastic Oscillator
- GFR 96.77
- RLMD 82.19
About GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.